GlassScriptPhysician profile
Dulce Novakovic
NPI 1396214375
$1,085.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,085.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $607.38 | 2021 | |
| Daiichi Sankyo INC. | $167.11 | 2021 | |
| Seagen INC. | $42.08 | 2021 | |
| Morphosys, US INC. | $37.24 | 2021 | |
| Emd Serono, INC. | $30.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.10 | 2021 | |
| Karyopharm Therapeutics INC. | $27.63 | 2021 | |
| Genzyme Corporation | $25.10 | 2021 | |
| Janssen Biotech, INC. | $19.78 | 2021 | |
| Blueprint Medicines Corporation | $19.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.12 | 2021 | |
| Amgen INC. | $15.17 | 2021 | |
| Gilead Sciences, INC. | $14.92 | 2021 | |
| Genentech USA, INC. | $14.87 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dulce Novakovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.